Markets:

Overview

News

Currencies

International

Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

165.35 -0.33 (-0.20%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

24 25 Next >

These S&P500 stocks are gapping in today's session ↗

February 25, 2025

Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Tuesday. Stay informed about the latest market trends.

Via Chartmill

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today ↗

February 24, 2025

Via Benzinga

Earnings To Watch: Masimo (MASI) Reports Q4 Results Tomorrow

February 24, 2025

Medical tech company Masimo (NASDAQ:MASI) will be reporting earnings tomorrow after the bell. Here’s what to look for.

Via StockStory

Integra LifeSciences (IART) Reports Earnings Tomorrow: What To Expect

February 24, 2025

Medical device company Integra LifeSciences (NASDAQ:IART) will be announcing earnings results tomorrow before market hours. Here’s what to look for.

Via StockStory

Curious about which S&P500 stocks are generating unusual volume on Friday? Find out below. ↗

February 21, 2025

Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.

Via Chartmill

Assessing Insulet: Insights From 6 Financial Analysts ↗

February 21, 2025

Via Benzinga

Earnings Scheduled For February 20, 2025 ↗

February 20, 2025

Via Benzinga

Looking for growth without the hefty price tag? Consider NASDAQ:PODD. ↗

February 14, 2025

Based on Fundamental Analysis it can be said that NASDAQ:PODD is a growth stock which is not overvalued.

Via Chartmill

$1000 Invested In Insulet 10 Years Ago Would Be Worth This Much Today ↗

February 07, 2025

Via Benzinga

Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst ↗

February 21, 2025

Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth.

Via Benzinga

These S&P500 stocks are moving in today's pre-market session ↗

February 21, 2025

Curious about the S&P500 stocks that are showing activity before the opening bell on Friday?

Via Chartmill

Insulet’s (NASDAQ:PODD) Q4: Beats On Revenue, Quarterly Revenue Guidance Slightly Exceeds Expectations

February 20, 2025

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 17.2% year on year to $597.5 million. Guidance for next...

Via StockStory

Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year

February 20, 2025

From Insulet Corporation

Via Business Wire

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today ↗

January 20, 2025

Via Benzinga

NASDAQ:PODD—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗

January 15, 2025

Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today ↗

January 03, 2025

Via Benzinga

Insulet Earnings: What To Look For From PODD

February 19, 2025

Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be announcing earnings results tomorrow after market close. Here’s what to expect.

Via StockStory

Why NASDAQ:PODD Is a Standout High-Growth Stock in a Consolidation Phase. ↗

February 06, 2025

Based on a technical and fundamental analysis of NASDAQ:PODD we ask: Why INSULET CORP (NASDAQ:PODD) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe

January 13, 2025

From Insulet Corporation

Via Business Wire

Stryker Had A Good Year Last Year; Here's How It's Looking For 2025 ↗

January 13, 2025

Reflecting its strong growth, on Monday the Relative Strength (RS) Rating for Stryker stock got an upgrade from 70 to 74.

Via Investor's Business Daily

Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

January 10, 2025

From Insulet Corporation

Via Business Wire

Looking Into Insulet's Recent Short Interest ↗

December 30, 2024

Via Benzinga

Exploring the Growth Potential of NASDAQ:PODD as It Nears a Breakout. ↗

December 25, 2024

Why INSULET CORP (NASDAQ:PODD) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

Lantheus Stock Doubled In A Year Amid Wide Use Of Its AI-Enabled Medical Devices ↗

January 07, 2025

Lantheus Holdings sees its Relative Strength Rating reach the 80-plus level.

Via Investor's Business Daily

Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today ↗

December 17, 2024

Via Benzinga

Inari Medical Stock Gets RS Rating Upgrade ↗

December 11, 2024

On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72.

Via Investor's Business Daily

Decoding 11 Analyst Evaluations For Insulet ↗

December 11, 2024

Via Benzinga

Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court

December 04, 2024

From Insulet Corporation

Via Business Wire

Novocure Stock Earns 96 RS Rating ↗

December 03, 2024

On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73.

Via Investor's Business Daily

Peering Into Insulet's Recent Short Interest ↗

November 27, 2024

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.